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Spherical and tubule nanocarriers for sustained drug
release
Tatsiana G Shutava1, Rawil F Fakhrullin2 and Yuri M Lvov3
We discuss new trends in Layer-by-Layer (LbL) encapsulation
of spherical and tubular cores of 50–150 nm diameter and
loaded with drugs. This core size decrease (from few
micrometers to a hundred of nanometers) for LbL
encapsulation required development of sonication assistant
non-washing technique and shell PEGylation to reach high
colloidal stability of drug nanocarriers at 2–3 mg/mL
concentration in isotonic buffers and serum. For 120–170 nm
spherical LbL nanocapsules of low soluble anticancer drugs,
polyelectrolyte shell thickness controls drug dissolution. As for
nanotube carriers, we concentrated on natural halloysite clay
nanotubes as cores for LbL encapsulation that allows high drug
loading and sustains its release over tens and hundreds hours.
Further drug release prolongation was reached with formation
of the tube-end stoppers.
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Polyelectrolyte coated drug nanocarriers
Spherical nanocarriers, especially emulsion and polymer
based systems, due to low toxicity of used materials and
easiness of preparation are under intensive investigation
for encasing therapeutic compounds. A wide range of
drugs and reporting molecules have been incorporated
into the nanovehicles that release the drugs in a pro-
longed or stimuli-responsive manner. Several nanocrys-
talline drug formulations have also been approved for
medical usage or are in clinical trials [1,2].
A state of art in the field is Layer-by-Layer (LbL) coated
nanocarriers since this approach allows for combining
drug-loaded core matrix with a shell of variable architec-
ture that can consist of polyelectrolytes, proteins, nano-
particles, and selected molecules of low molecular
weight. On the basis of electrostatic interaction between
adsorbing layers, LbL shell preparation does not require
harsh conditions to interlock different components
together in the same coating. As an advantage, its archi-
tecture in the direction normal to the core surface is
decided beforehand [3–5]. The possibility of scaling-
down and combining with different core preparation
techniques makes LbL assembly a highly promising
approach for nanomedicine applications.
Nevertheless, only within the recent five years the design
of the LbL nanovehicle systems reaches the level of
properties desirable for efficient systemic delivery: mini-
mum toxicity due to biodegradable materials, stability of
nanocolloid as an isotonic formulation, prolonged release
of encased drug in vitro and in vivo, effective endosomal
escape, and extended serum half-life that allows for
prolonged exposure of cells to the treatment, active
targeting and tumour cell uptake [1,6]. In a proof-of-
concept study, Hammond et al. [7] recently demon-
strated a systemic co-delivery of doxorubicin and siRNA
in NCr nude mice bearing subcutaneous xenograft
tumours of luciferase-expressing MDA-MB-468 cells
via 120 nm LbL coated liposomes. Liposomes containing
5.5 wt.% of doxorubicin were used as a core. By assem-
bling MRP1 siRNA in alternation with poly-L-arginine as
a multilayer shell, a high loading of the gene silencing
RNA per nanoparticle was reached. A layer of hyaluronic
acid deposited atop the shell efficiently shields it from
recognition by immune system and enhances the nano-
capsules uptake by tumour tissue through the interaction
of hyaluronic acid with CD4 glycoprotein. In another
study, LbL-coated paclitaxel (PTX) nanoparticles with
attached tumor-specific mAb 2C5 antibody effectively
target the nucleosome monolayer in the ELISA assay.
Attached antibody enhances in vitro toxicity of the nano-
capsules towards MCF-7 and BT-20 cancer cell lines [8].
Yet in another work, bovine serum albumin (BSA) nano-
particles of a 200 nm diameter modified with polyallyla-
mine hydrochloride/polystyrene sulfonate (PAH/PSS)
multilayers were used for encapsulation of doxorubicin
and covalent modification with aptamer AS1411 to target
the over-expressed nucleolin on cancer cell membrane
[9].
Apart from preset architecture of the coating as above, the
polyelectrolyte shell stabilizes nanocrystals of poorly
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